(Q43863224)

English

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials.

scientific article published on 14 October 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Anthony M Joshua

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

13

object named as

I F Tannock

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Arnoud J Templeton

1

object named as

A J Templeton

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Francisco Vera-Badillo

2

object named as

F E Vera-Badillo

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

L Wang

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

M Attalla

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

P De Gouveia

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

R Leibowitz-Amit

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

J J Knox

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

M Moore

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

S S Sridhar

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

G R Pond

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

14 October 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

2972-2977

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT397

21 January 2018

Reducing patient eligibility criteria in cancer clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT397

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT397

21 January 2018

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT397

21 January 2018

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT397

21 January 2018

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT397

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT397

21 January 2018

Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT397

21 January 2018

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT397

21 January 2018

Efficacy vs. effectiveness--docetaxel and prednisone in hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT397

21 January 2018

The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT397

21 January 2018

From efficacy to effectiveness in the face of uncertainty: indication creep and prevention creep.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT397

21 January 2018

Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT397

21 January 2018

Identifiers

10.1093/ANNONC/MDT397

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24126362%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43863224&oldid=2103992119"